Precertification Required on Four New Part B Injectables

Amerigroup* is adding four new injectable drugs to the 2015 Medicare Advantage list of Part B Injectables / Infusibles requiring precertification.

What this means to you: As of March 1, 2015, providers must call for prior authorization of these drugs listed below.

1. Benlysta (belimumab) for treatment of lupus (SLE) (J0490)
   Drugs billed with NOC HCPCS J code (J3490)

2. Iluvien (fluocinolone acetonide injection): for treatment of diabetic macular edema (DME) (unlisted, no J code established at this time)

3. Lemtrada (alemtuzumab injection): for treatment of relapsing forms of multiple sclerosis (MS) (unlisted, no J code established at this time)

4. Opdivo (nivolumab) for treatment of unresectable or metastatic melanoma (unlisted, no J code established at this time)

Please note for drugs currently billed under the Not Otherwise Classified J code (J3490), the plan’s denial will be for the drug, and not the HCPCS.

To contact the plan for prior authorization of these services, see below:
Phone: 866-797-9884 Option 5
Fax: 866-959-1537
Email: maspecialtypharm@anthem.com

*In Texas, Amerigroup members in the Medicaid Rural Service Area are served by Amerigroup Insurance Company; all other Amerigroup members are served by Amerigroup Texas, Inc.

Amerivantage is an HMO plan with a Medicare contract and a contract with the Texas Medicaid program. Enrollment in Amerivantage depends on contract renewal.